Overview

Location [1]
11p14.3
Pathway
DNA damage/repair
Protein [2]
Fanconi anemia group F protein
Synonyms [1]
FAF

Fanconi anemia, complementation group F (FANCF) is a gene that encodes a protein that is a member of the Fanconi anemia complementation group. The protein complex functions in the heterogeneous recessive disorder Fanconi anemia that causes cytogenetic instability, hypersensitivity to DNA crosslinking agents, increases chromosomal breakage, and defective DNA repair. Missense, nonsense, and silent mutations are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.

FANCF is altered in 0.98% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, bladder urothelial carcinoma, and glioblastoma having the greatest prevalence of alterations [3].

FANCF GENIE Cases - Top Diseases

The most common alterations in FANCF are FANCF Mutation (0.49%), FANCF Nonsense (0.03%), FANCF Frameshift (0.02%), FANCF Amplification (0.02%), and FANCF R216P (0.02%) [3].

FANCF GENIE Cases - Top Alterations

Significance of FANCF in Diseases

Malignant Solid Tumor +

Breast Carcinoma +

Prostate Adenocarcinoma +

Ovarian Carcinoma +

Prostate Carcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Pancreatic Adenocarcinoma +

Urothelial Carcinoma +

Endometrial Carcinoma +

Non-Hodgkin Lymphoma +

Non-Small Cell Lung Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Cervical Carcinoma +

Pancreatic Carcinoma +

Small Cell Lung Carcinoma +

Clear Cell Renal Cell Carcinoma +

Colorectal Carcinoma +

Cholangiocarcinoma +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Head And Neck Squamous Cell Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Osteosarcoma +

Soft Tissue Sarcoma +

Squamous Cell Lung Carcinoma +

Leiomyosarcoma +

Bladder Urothelial Carcinoma +

Esophageal Carcinoma +

Colorectal Adenocarcinoma +

Malignant Intestinal Neoplasm +

Malignant Esophagogastric Neoplasm +

Invasive Breast Carcinoma +

Cancer +

Kidney Carcinoma +

Malignant Ovarian Epithelial Tumor +

Melanoma +

Ampulla Of Vater Carcinoma +

Anal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Bile Duct Adenocarcinoma +

Biliary Tract Carcinoma +

Diffuse Large B-Cell Lymphoma +

Esophageal Adenocarcinoma +

Ewing Sarcoma +

Gastric Adenocarcinoma +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Low Grade Ovarian Serous Adenocarcinoma +

Malignant Gastric Neoplasm +

Malignant Mesothelioma +

Malignant Small Intestinal Neoplasm +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mesothelioma +

Multiple Myeloma +

Neuroblastoma +

Ovarian Clear Cell Adenocarcinoma +

Pancreatic Ductal Adenocarcinoma +

Penile Carcinoma +

Rhabdomyosarcoma +

Uveal Melanoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.